Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Novartis has won an approval to sell its landmark CAR-T therapy Kymriah in Japan at a discount price as it continues its slow rollout around the globe while it gradually builds up its manufacturing operations.